JPH0137377B2 - - Google Patents
Info
- Publication number
- JPH0137377B2 JPH0137377B2 JP14914683A JP14914683A JPH0137377B2 JP H0137377 B2 JPH0137377 B2 JP H0137377B2 JP 14914683 A JP14914683 A JP 14914683A JP 14914683 A JP14914683 A JP 14914683A JP H0137377 B2 JPH0137377 B2 JP H0137377B2
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- combination
- blood
- effect
- alloxan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 20
- 239000008280 blood Substances 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 15
- 229930003427 Vitamin E Natural products 0.000 claims description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 10
- 239000011709 vitamin E Substances 0.000 claims description 10
- 229940046009 vitamin E Drugs 0.000 claims description 10
- 235000019165 vitamin E Nutrition 0.000 claims description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- 239000003524 antilipemic agent Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 26
- 230000000694 effects Effects 0.000 description 20
- 229940088594 vitamin Drugs 0.000 description 19
- 229930003231 vitamin Natural products 0.000 description 19
- 235000013343 vitamin Nutrition 0.000 description 19
- 239000011782 vitamin Substances 0.000 description 19
- 150000003722 vitamin derivatives Chemical class 0.000 description 19
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 8
- -1 lipid peroxide Chemical class 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 235000019156 vitamin B Nutrition 0.000 description 4
- 239000011720 vitamin B Substances 0.000 description 4
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000219823 Medicago Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001278 effect on cholesterol Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14914683A JPS6041611A (ja) | 1983-08-17 | 1983-08-17 | 血中脂質低下剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14914683A JPS6041611A (ja) | 1983-08-17 | 1983-08-17 | 血中脂質低下剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6041611A JPS6041611A (ja) | 1985-03-05 |
| JPH0137377B2 true JPH0137377B2 (de) | 1989-08-07 |
Family
ID=15468773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14914683A Granted JPS6041611A (ja) | 1983-08-17 | 1983-08-17 | 血中脂質低下剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6041611A (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2547400B2 (ja) * | 1986-02-27 | 1996-10-23 | 昭和電工株式会社 | 動物用薬剤 |
| JP3283274B2 (ja) * | 1991-06-15 | 2002-05-20 | サントリー株式会社 | 新規組成物 |
| WO2002034261A1 (fr) * | 2000-10-23 | 2002-05-02 | Sankyo Company, Limited | Compositions hypocholesterolemiantes |
| US6916849B2 (en) | 2000-10-23 | 2005-07-12 | Sankyo Company, Limited | Compositions for improving lipid content in the blood |
| CN1240379C (zh) | 2000-11-07 | 2006-02-08 | 三共株式会社 | 过氧化脂质降低剂组合物 |
| CA2433285C (en) | 2000-12-14 | 2009-06-23 | Sankyo Company, Limited | Blood lipid ameliorating composition |
| CN1287787C (zh) * | 2000-12-14 | 2006-12-06 | 三共株式会社 | 血液脂质改善剂组合物 |
| US7037934B2 (en) | 2000-12-14 | 2006-05-02 | Sankyo Company, Limited | Blood lipid ameliorant composition |
| TWI284529B (en) * | 2000-12-18 | 2007-08-01 | Sankyo Co | A composition for lowering triglyceride |
| CN100413866C (zh) * | 2002-08-02 | 2008-08-27 | 中国人民解放军军事医学科学院放射医学研究所 | 核黄素衍生物及其制备方法与应用 |
-
1983
- 1983-08-17 JP JP14914683A patent/JPS6041611A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6041611A (ja) | 1985-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS60109522A (ja) | 神経病の治療のためのビロバリド含有製剤組成物 | |
| JPH08253416A (ja) | フェノフィブレートとビタミンｅの組成物およびその 治療上の用途 | |
| IE60923B1 (en) | Pharmaceutical composition for oral administration, based on a diphosphonic acid derivative | |
| JP2881442B2 (ja) | ジルチアゼムの遅放出性無酸医薬製剤及びその製法 | |
| JPH11514629A (ja) | 安定な甲状腺ホルモン含有薬剤 | |
| JP2010533168A (ja) | ユビデカレノンを含有する多層錠ビタミン複合製剤 | |
| IL102519A (en) | Oral Dosage Formulations of Dioxy Purine Nucleosides Containing Water-Soluble Antacids | |
| AT400521B (de) | Verfahren zur herstellung einer festen oralen pharmazeutischen ketotifenzusammensetzung | |
| JPH0137377B2 (de) | ||
| WO2011152875A1 (en) | Chewable, swallowable and effervescent solid dosge form for oral delivery of pharmaeutical actives | |
| EP0521057B1 (de) | Ipriflavone enthaltende pharmazeutische zubereitungen, verfahren zur herstellung und therapeutische verwendung | |
| Stolk et al. | Serum levels of 8‐methoxypsoralen: difference between two oral methods of administration | |
| US3928609A (en) | Non-alcoholic theophylline product | |
| JPH04295428A (ja) | 抗アレルギー剤 | |
| UA74793C2 (en) | Bioavailable pharmaceutical composition of isotretinoin and process for preparing such composition | |
| US5504105A (en) | Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use | |
| JPS60120812A (ja) | 糖尿病性骨減少症治療剤 | |
| JPH05255126A (ja) | 苦味低減組成物 | |
| TW202128150A (zh) | ３＇—［（２ｚ）—［１—（３，４—二甲基苯基）—１，５—二氫—３—甲基—５—側氧基—４ｈ—吡唑—４—亞基］肼基］—２＇—羥基—［１，１＇—聯苯基］—３—甲酸及其鹽配製物 | |
| JP3035328B2 (ja) | 血中脂質低下剤 | |
| JPS5824514A (ja) | 消化性潰瘍治療剤 | |
| US3891749A (en) | Digestive pharmaceutical composition comprising S-carboxymethyl cysteine for reducing viscosity of respiratory tract secretions, and method of treating therewith | |
| JP6087988B2 (ja) | 鼻汁分泌抑制用組成物 | |
| US3574834A (en) | Medicinal soporific composition | |
| JP2000080034A (ja) | 風邪用組成物 |